Advanced Medical Solutions Grp PLC Appointment of Adviser (2813R)
04 November 2021 - 06:00PM
UK Regulatory
TIDMAMS
RNS Number : 2813R
Advanced Medical Solutions Grp PLC
04 November 2021
04 November 2021
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Appointment of Adviser
Winsford, UK: Advanced Medical Solutions plc (AIM: AMS), the
surgical and advanced wound care specialist company, today
announces the appointment of HSBC Bank plc ("HSBC") as its Joint
Broker and Joint Financial Adviser, with immediate effect. Investec
Bank plc will continue to act as Nominated Adviser, Joint Broker
and Joint Financial Adviser to the Company.
- End -
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations Manager
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Mary-Jane Elliott / Matthew Neal / Matthew
Cole
Investec Bank plc - Nominated Adviser, Tel: +44 (0) 20 7597
Joint Broker and Joint Financial Adviser 5970
Daniel Adams / Gary Clarence
HSBC Bank plc - Joint Broker and Joint Tel: 44 (0)20 7991
Financial Adviser 8888
Sam McLennan / Joe Weaving
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical and woundcare markets, focused on quality outcomes for
patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. In 2019, the Group made two acquisitions: Sealantis,
an Israeli medical device company with a patent-protected sealant
technology platform; and Biomatlante, an established developer and
manufacturer of innovative surgical biomaterial technologies based
in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a
leading coater and converter of materials predominately for
woundcare and bio-diagnostics products based in the UK.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany, the
Czech Republic and Russia. The Group has R&D innovation hubs in
the UK, Germany, France and Israel. Established in 1991, the Group
has more than 700 employees. For more information, please see
www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPFSFFUDEFSELF
(END) Dow Jones Newswires
November 04, 2021 03:00 ET (07:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Mar 2023 to Mar 2024